Clinical Trial Detail

NCT ID NCT03934814
Title Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors I-Mab Biopharma Co. Ltd.
Indications

peritoneum cancer

fallopian tube cancer

lymphoma

ovary epithelial cancer

Advanced Solid Tumor

diffuse large B-cell lymphoma

lung non-small cell carcinoma

bladder urothelial carcinoma

B-cell lymphoma

Therapies

TJ011133

Pembrolizumab + TJ011133

Rituximab + TJ011133

Age Groups: adult senior

No variant requirements are available.